|
|
|
|
Vol. 298, Issue 1, 116-121, July 2001
Department of Pharmacology, University of Michigan Medical School,
Ann Arbor, Michigan
The
guanosine-5'-O-(3-[35S]thio)triphosphate
([35S]GTP
S) binding assay for the determination of
relative opioid efficacy has been adapted to measure G protein
activation in digitonin-permeabilized C6 rat glioma cells expressing a
cloned µ-opioid receptor. The µ-agonist
[D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
(DAMGO) caused a 3-fold increase in [35S]GTP
S binding
over basal in a naloxone-sensitive manner. Relative µ-agonist
efficacy was DAMGO > fentanyl
morphine > buprenorphine. Nalbuphine showed no efficacy. G protein activation by
receptors has been predicted to occur by random encounter. In this
model a reduction in the number of receptors will decrease the rate of
G protein activation but not the maximum number of G proteins activated. To test this model C6 µ cells were treated with the irreversible µ-antagonist
-funaltrexamine (10 nM) prior to
permeabilization. This reduced the number of µ-opioid receptors
determined with [3H]diprenorphine to 23 ± 3% of
control with no change in affinity. A commensurate reduction (to
29 ± 10% of control) in the level of [35S]GTP
S
binding stimulated by DAMGO was observed, but the
t1/2 for [35S]GTP
S binding
remained unchanged. Thus, random encounters of receptor and G protein
failed to occur in this permeabilized cell preparation. A model that
assumes an organized association of G proteins with receptors better
describes the activation of G proteins by opioid µ-receptors.
This article has been cited by other articles:
![]() |
D. L. Roman, J. N. Talbot, R. A. Roof, R. K. Sunahara, J. R. Traynor, and R. R. Neubig Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay Mol. Pharmacol., January 1, 2007; 71(1): 169 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Walker, M. J. Picker, A. Granger, and L. A. Dykstra Effects of Opioids in Morphine-Treated Pigeons Trained to Discriminate among Morphine, the Low-Efficacy Agonist Nalbuphine, and Saline J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 150 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Martin, M. B. Ruckle, S. L. VanHoof, and P. L. Prather Agonist, Antagonist, and Inverse Agonist Characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a Selective delta -Opioid Receptor Ligand J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 661 - 671. [Abstract] [Full Text] [PDF] |
||||